Redeye comments briefly on Evolution’s press release regarding a review initiated by UKGC due to Evo...
Redeye comments on Freemelt’s plan to resolve a SEK100m rights issue, with 90% secured through subsc...
Redeye comments on Gasporox’s convertible debt financing.
Accenture Q1'25 grew 8% (+3% vs cons), driven by a broad base Raises FY guidance from 3-6% growth to...
Imflifidase shows robust efficacy results in phase 2 among patients with severe GBS.
On December 18th, STENOCARE announced that the company has resolved a rights issue of up to DKK 20.
Avtech has secured its second-largest contract, signing an agreement with LATAM Airlines valued at E...
Enersense's wind power development portfolio has been divested, and losses from non-core operations ...
Redeye comments on Surgical Science announcing an opportunistic bolt-on deal by offering to acquire ...
Redeye comments on Egetis investor day yesterday, that focused on the commercialization of Emcitate ...
The divestment price estimate of Enersense’s wind power portfolio (2.
Förra veckan aviserade kontraktstillverkaren Hanza förvärvet av finska Leden Group, en ledande kontr...
New defence order from BAE Systems worth SEK 53m Additional order from Denmark also expected near-te...
Obducat AB (publ) meddelade den 18 december 2024 att Obducats dotterbolag Obducat Europe GmbH har er...
I torsdags aviserade industrikoncernen AGES Industri pågående diskussioner kring en eventuell fusion...
Redeye comments on a new additional supplier of Terbinafine that already holds an EU certificate of ...
Redeye leaves a comment following Lipum’s announcement of a grant from Eurostars.
Titania meddelade den 17 december år 2024 att bolaget har tecknat ett avtal om förvärv av fastighete...
Redeye comments on the successful directed share issue of NOK100m and EUR1m primary bid offering.
Alisa Bank issued a profit warning for 2024, lowering expectations for total income and profitabilit...